Related Experiment Video

Updated: Nov 24, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

Zhen Li1, Wei Zou2, Ji Zhang1

  • 1Department of the Third Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.

Frontiers in Pharmacology
|December 28, 2020
PubMed

Insights

CDK4/6 inhibitors combined with endocrine therapy show promise for advanced ER+ breast cancer. Overcoming drug resistance, driven by cell proliferation, is crucial for improving patient outcomes and requires further research into resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • CDK4/6 inhibitors combined with endocrine therapy are effective for advanced ER+ breast cancer.
  • Drug resistance to CDK4/6 inhibitors is a significant challenge in breast cancer treatment.
  • Understanding resistance mechanisms is vital for improving therapeutic strategies.

Purpose of the Study:

  • To review the mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer.
  • To categorize resistance pathways into upstream and downstream mechanisms.
  • To discuss strategies for overcoming resistance and identify new therapeutic targets.

Main Methods:

  • Literature review of CDK4/6 inhibitor resistance mechanisms.
  • Analysis of cell signaling pathways involved in therapy resistance.
  • Discussion of clinical implications and future research directions.

Main Results:

  • Overactivation of the cyclin-CDK-Rb axis is a primary driver of resistance.
  • Resistance mechanisms involve both upstream and downstream signaling pathways.
  • Identification of potential targets for overcoming acquired resistance.

Conclusions:

  • Clarifying resistance mechanisms is essential for developing effective treatments.
  • Targeting specific pathways may overcome CDK4/6 inhibitor resistance.
  • Further research is needed to translate these findings into clinical applications.
Keywords:
CDK4/6 inhibitordownstream bypass signalingendocrine resistanceluminal breast cancerupstream response signaling

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.5K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.2K